EFFECTIVE this week the long anticipated hepatitis C treatment for genotypes 1 and 4 (PD 16 Dec 16) has been PBS listed, bringing enthusiastic welcoming comments from Hepatitis Australia.
The combination of elbasvir and grazoprevir (brand name Zepatier from MSD) was funded effective 01 Jan and marks an important day for a small but significant proportion of the 227,000 people with the condition, Hepatitis Australia said.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jan 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jan 17
